home / stock / hcwb / hcwb news

HCWB News and Press, HCW Biologics Inc. From 11/08/23

Stock Information
Company Name: HCW Biologics Inc.
Stock Symbol: HCWB
Market: NASDAQ
Website: hcwbiologics.com
Menu
HCWB HCWB Quote HCWB Short HCWB News HCWB Articles HCWB Message Board
Get HCWB Alerts

News, Short Squeeze, Breakout and More Instantly...
HCWB - Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Showed HCW9218 clinical safety and tumor response endpoints for 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics In...
HCWB - Expected US Company Earnings on Monday, November 6th, 2023

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

HCWB - Expected earnings - HCW Biologics Inc.

HCW Biologics Inc. (HCWB) is expected to report for Q1 2024

HCWB - Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the li...
HCWB - HCW Biologics director Gary Winer buys shares worth $3.3k - filing

2023-09-18 11:14:36 ET More on HCW Biologics Seeking Alpha’s Quant Rating on HCW Biologics Historical earnings data for HCW Biologics Financial information for HCW Biologics For further details see: HCW Biologics director Gary Winer buys shares wor...

HCWB - HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 - 13, 2023

MIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the l...

HCWB - HCW Biologics GAAP EPS of -$0.12 beats by $0.04

2023-08-11 10:58:15 ET HCW Biologics press release ( NASDAQ: HCWB ): Q2 GAAP EPS of -$0.12 beats by $0.04 . Net revenue of $120.4M (-27.8% Y/Y). As of June 30, the company held $17.4M in cash, cash equivalents and U.S. Treasury bills of short duration. With thi...
HCWB - HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the li...

HCWB - HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

MIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the li...

HCWB - HCW Biologics GAAP EPS of -$0.14 beats by $0.02, revenue of $0.01M

2023-05-09 08:57:22 ET HCW Biologics press release ( NASDAQ: HCWB ): Q1 GAAP EPS of -$0.14 beats by $0.02 . Revenue of $0.01M (-99.4% Y/Y). As disclosed above, the Company entered into a development line of credit agreement for the buildout of the Company’s ...
Previous 10 Next 10